Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
14 11월 2024 - 9:11PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
November,
2024
Commission
File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
¨ No x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
|
Date:
November 14, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
November 14, 2024
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Intimation
under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
This is to inform that the Company has received
an order dated November 12, 2024, from COFEPRIS (Comisión Federal para la Protección Contra Riesgos Sanitarios) health department
of Mexico. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read
with Schedule III Para A Sub Para 20 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:
A |
Name of the authority |
: |
COFEPRIS (Comisión Federal para la Protección Contra Riesgos Sanitarios) |
B |
Nature and details of the action(s) taken, initiated or order(s) passed |
: |
The drug regulatory body of Mexico (Comisión Federal para la Protección contra Riesgos Sanitarios) has imposed a penalty of MXN 651, 420 (~INR 27 Lakh) on the Company for deviation from prescribed guidelines in filing intimation of import of a reference standard for one of our APIs. Additionally, the fine was imposed due to an error in the date of the invoice and also name of the reference standard Vs import license. |
C |
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority |
: |
13th November 2024 |
D |
Details of the violation(s)/ contravention(s) committed or alleged to be committed |
: |
As stated in “B” above |
E |
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible |
: |
MXN 651,420 (~INR 27 Lakh) |
This is for your information and record.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
Dr Reddys Laboratories (NYSE:RDY)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Dr Reddys Laboratories (NYSE:RDY)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024